This year’s Leveraging the Laboratory Conference will provide an inside look at how laboratory outreach programs were provided new testing and generated new revenue streams for their health systems throughout the course of the COVID-19 pandemic and beyond.
Managing an outreach laboratory requires more than just sound technical skills. It also requires an firm understanding of the various financial components that affect the way a lab operates and performs in order to demonstrate, and prove, the positive financial impact of an outreach program.
When most of the world was still struggling to understand how COVID-19 would affect their lives, Atria Senior Living took steps to protect their vulnerable residents and staff.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update. In this episode, Dr. Morice and Bobbi Pritt, M.D., explain Mayo Clinic Laboratories, review its history, and describe how its work furthers Mayo Clinic’s mission.
Dr. Dollahite received world-class cancer treatment from a web of health care organizations, including Mayo Clinic in Rochester, Minnesota. Yet she never left New York; most of her treatment occurred in Ithaca. What made that possible was Cayuga Medical Center’s collaborative relationship with Mayo Clinic. Genetic testing at Mayo Clinic Laboratories provided important information about Dr. Dollahite’s cancer.
For community health care providers, owning a laboratory has been likened to shoveling money down a giant drain. Cayuga Medical Center is challenging that narrative. Instead of selling, Cayuga is investing in its lab — which it considers a value center as well as a key part of patient service.
Cayuga Medical Center sought to challenge the narrative that a hospital’s lab is an expensive liability by positioning themselves as the laboratory of choice in their area.
UofL Health – UofL Hospital physicians and laboratory scientists faced challenges in the ordering of autoimmune and paraneoplastic panels: duplicate orders that add unnecessary cost and omitted test orders that could provide the key to the right diagnosis for patients.
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.
Mayo Clinic’s Biochemical Genetics Laboratory has announced an updated second-tier test to detect Krabbe disease (KD) that uses psychosine (PSY) as a disease marker. The new test method has significantly higher sensitivity to detect this devastating disease in infants and allows identification of KD patients with minimal psychosine elevations.
Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.